CAJ | 학술논문

ER、PR、HER-2在乳腺癌中是指导治疗和判断预后的重要的生物学标志物。随着乳腺癌的病情进展，ER、PR、HER-2的表达在原发灶及转移灶中可能存在差异。目前临床医师已意识到对转移灶进行受体检测的必要性。该文结合目前的研究现状就上述问题进行综述。
ER、PR、HER-2재유선암중시지도치료화판단예후적중요적생물학표지물。수착유선암적병정진전，ER、PR、HER-2적표체재원발조급전이조중가능존재차이。목전림상의사이의식도대전이조진행수체검측적필요성。해문결합목전적연구현상취상술문제진행종술。
ER, PR, HER-2 are signiifcant biological markers in guiding the choice of treatment and evaluating clinical prognosis. As the progression of tumor cells, the expressions of these receptors in recurrent tumors may be different from primary tumors. Nowadays clinicians have realized the necessity of receptor detection in the metastatic lesions. This article summarized the current research status on the above issues.